Clinical Research Directory
Browse clinical research sites, groups, and studies.
Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use
Sponsor: Otsuka Pharmaceutical Co., Ltd.
Summary
To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be collected.
Official title: AJOVY Subcutaneous Injection Long-term Specified Use-results Survey
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1000
Start Date
2022-04-20
Completion Date
2029-06-22
Last Updated
2025-03-21
Healthy Volunteers
No
Conditions
Interventions
Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution
The usual adult dose is 225 mg of fremanezumab (genetical recombination) administered subcutaneously as a single dose once every 4 weeks or 675 mg administered subcutaneously as a single dose once every 12 weeks.
Locations (1)
Pharmacovigilance Department
Osaka, Japan